Updates are available Correction dated 2025-06-23

Article History

Received: 28 January 2025

Accepted: 26 April 2025

First Online: 20 May 2025

Change Date: 23 June 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12282-025-01736-0

Declarations

:

: TY reports receiving payment/honoraria from Eli Lilly Japan, AstraZeneca, Chugai Pharmaceutical, Kyowa Kirin, Pfizer, MSD, Eisai, and Novartis Pharma. YT reports grant/contract from Eli Lilly; receiving payment/honoraria from Eli Lilly Japan, Pfizer, Chugai Pharmaceutical, Daiichi Sankyo, MSD, and AstraZeneca. YO reports receiving honoraria from Daiichi Sankyo, Pfizer, Eli Lilly Japan, and Kyowa Kirin. KW reports receiving payment/honoraria from Chugai Pharmaceutical, Eli Lilly Japan, Nippon Kayaku, Kyowa Kirin, Novartis Pharma, Taiho Pharmaceutical, Eisai, Pfizer, Shionogi Pharmaceutical, Daiichi Sankyo, and AstraZeneca. SEN reports receiving payment/honoraria from Eli Lilly Japan, Pfizer, Daiichi Sankyo, Chugai Pharmaceutical, Eisai, MSD, Gilead Sciences, and Kyowa Kirin; participation on a Data Safety Monitoring Board or Advisory Board for Daiichi Sankyo and Chugai Pharmaceutical. NS (Shibata) reports research grants to institution from Daiichi Sankyo, AstraZeneca, and MSD; receiving consulting fees from Kyowa Kirin; receiving lecture honoraria from Kyowa Kirin, MSD, Daiichi Sankyo, Chugai Pharmaceutical, Pfizer, Eisai, Yakult, Taiho Pharmaceutical, Eli Lilly Japan, Nippon Kayaku, Merck Biopharma, and Bristol Myers Squibb; participation on an Advisory Board for Kyowa Kirin and Daiichi Sankyo. CO reports receiving payment/honoraria from Eli Lilly Japan. HB reports receiving payment/honoraria from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Eisai, Kyowa Kirin, AstraZeneca, Pfizer, and MSD. NT (Tsunoda) reports receiving payment/honoraria from Eli Lilly Japan, Pfizer, Chugai Pharmaceutical, AstraZeneca, and Eisai. KK reports receiving payment/honoraria from Pfizer and Chugai Pharmaceutical. MT (Takada) reports grants to institution from Yakult and Guardant Health Japan; receiving payment/honoraria from Daiichi Sankyo, AstraZeneca, Taiho Pharmaceutical, Eli Lilly Japan, MSD, Pfizer, Eisai, Chugai Pharmaceutical, Devicor Medical Japan, and Mitaka Kohki. NT (Toriguchi), NS (Sekine), and TK report being employees of Eli Lilly Japan and minor shareholders of Eli Lilly and Company. SS reports grants to institution from Taiho Pharmaceutical, Eisai, Takeda Pharmaceutical, Chugai Pharmaceutical, and Daiichi Sankyo; contracted clinical trials for MSD, AstraZeneca, Gilead Sciences, Eli Lilly Japan, Sanofi, Chugai Pharmaceutical, and Daiichi Sankyo; receiving payment/honoraria from Chugai Pharmaceutical, Kyowa Kirin, MSD, Novartis Pharma, Eisai, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, AstraZeneca, Pfizer, Taiho Pharmaceutical, Ono Pharmaceutical, Nippon Kayaku, Gilead Sciences, and Exact Sciences; participation on a Data Safety Monitoring Board or Advisory Board for Chugai/Roche, AstraZeneca, Eli Lilly Japan, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD; being an executive board member for Japan Breast Cancer Research Group (JBCRG), Japanese Breast Cancer Society (JBCS), Japanese Society of Medical Oncology (JSMO), and Breast International Group (BIG). YS reports receiving payment/honoraria from Pfizer, Daiichi Sankyo, Eli Lilly Japan, MSD, Kyowa Kirin, Celltrion Healthcare Japan, AstraZeneca, Eisai, Chugai Pharmaceutical, Nippon Kayaku, and Sysmex. SM reports grants to institution from Eisai; receiving payment/honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, and Ono Pharmaceutical. NM grants to institution from Chugai Pharmaceutical, Eli Lilly Japan, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis Pharma, Gilead Sciences, and Ono Pharmaceutical; receiving payment/honoraria from Chugai Pharmaceutical, Pfizer, AstraZeneca, Eli Lilly Japan, Daiichi Sankyo, and Eisai; being a representative/member of Board of Directors (unpaid) for JBCRG, JBCS, Japan Society of Clinical Oncology (JSCO), and Japan Association of Breast Cancer Screening (JABCS). YK, MY, MT (Tsukabe), FF, and KY report no conflict of interest regarding this manuscript.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.The present study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice (ICH-GCP) Guideline, and Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan. The protocol [no. 23136 (T34)] was approved by the institutional review board of Osaka University Hospital (Osaka, Japan).

: Patients provided consent to the use of their data by either providing written informed consent or on an opt-out basis.